Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib in Advanced Cancer with Hepatic Dysfunction
NCT02070549Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2014
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of trametinib in solid tumor (advanced stage), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 28 days, Dose-Limiting Toxicity at 28 days and 1 more. Started Mar 2014; status: completed.
02
Drugs
trametinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02070549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02070549.